| Autor: |
Mengping Long, Min Ying, Xinguang Wang, Jinbo Wu, Xuejiao Lina Hu, Zhaorong Guo, Baosheng Liang, Yuntao Xie, Jinfeng Li, Tianfeng Wang, Tao Ouyang, Aihua Sun, Xiaohua Zhou, Zhaoqing Fan, Yiqiang Liu, Taobo Hu |
| Rok vydání: |
2022 |
| DOI: |
10.21203/rs.3.rs-1818429/v1 |
| Popis: |
BackgroundHER2-low-positive breast cancers are reported to have distinct clinical and molecular features from HER2-zero tumors in ER-positive breast cancer. However, the association between HER2-status with response to endocrine therapy is largely unknown. MethodsIn this study, we conducted a retrospective analysis to compare the response of ER-positive breast cancer to neoadjuvant endocrine therapy (NET), neoadjuvant chemotherapy (NCT) and survival according to HER2-status.ResultsPathological complete response (pCR) in primary tumor (ypT0/isNx) is significantly lower in HER2-low-positive breast cancer than in HER2-zero tumors for NET cohort (18 out of 233 [7.7%] vs 9 out of 45 [20%]) but not for NCT cohort (28 out of 204 [13.3%] vs 5 out of 36 [13.9%]). HER2-zero tumors consistently show higher ypT0/isNx pCR ratio than HER2-low-positive breast cancer in all endocrine therapy duration groups including 3-10months, 11-20months and 21-30months groups. Multi-variable logistic regression analyses showed that HER2-low-positive expression is a risk factor for poor response to NET. In patients receiving NET, HER2-low-positve breast tumors has better disease-free survival compared with HER2-zero while no significance difference was detected with overall survival. ConclusionsOur results demonstrated that HER2-low-positive breast tumors was a distinct subtype in ER-positive breast cancers and was associated with endocrine therapy resistance. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
